펩트론

087010KOSDAQ기초 의약물질 제조업

45.4 / 100

Reference Date: 2026-07-24

Financial Score10.5 / 40

News Sentiment17.9 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 49.6% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Peptron develops smart pharmaceuticals using peptide engineering and sustained-release technology, operating a GMP large-scale production facility for clinical trials and commercial products. The pharmaceutical industry is characterized by high R&D costs and long-term profitability, with the sustained-release drug sector maintaining an oligopolistic structure due to high manufacturing barriers even after patent expirations.

Number of Employees

160people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

17.86Industry Average 1.260.0Point

14.2x industry avg (risky)

ROE

-9.41Industry Average -6.033.5Point

1.6x industry avg (good)

Debt Ratio

21.10Industry Average 6.620.0Point

3.2x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼16.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -22.9% (improving, 3yr)

Detailed News Sentiment

20 totalPositive 6Neutral 3Negative 11Average Sentiment Score 71.8

Positive
"200조 비만약 시장 잡아라"?K바이오 '빅딜' 승부수
국내 제약바이오 기업들의 비만치료제 시장 진출 가속화로 펩트론의 미래 성장 가능성이 높아짐.
Neutral
시총 100대 기업 임원 평균 54.2세…여성 늘고 젊은 임원은 희소
Analysis of CEO age trends in top Korean corporations indicates a slight increase but lacks direct impact on specific stock performance.
Negative
기대 컸는데 '삐끗'… K바이오 겹악재에 자금수혈 위기
K바이오 관련 부정적 이슈로 펩트론의 주가가 큰 타격을 입었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 108,800Won52-week high 386,00052-week low 103,600

1-month return0.0Point

1m -49.63% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14